| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
|
| | 1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone Basic information |
| Product Name: | 1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone | | Synonyms: | LY 255283;1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOLE-5-YL)HEPTYL]OXY]PHENYL]-ETHANONE;5'-Ethyl-2'-hydroxy-4'-[6-methyl-6-(1H-tetrazol-5-yl)heptyloxy]acetophenone;CGS 23356;1-[5-ethyl-2-hydroxy-4-[6-methyl-6-(2H-tetrazol-5-yl)heptoxy]phenyl]ethanone;Ethanone, 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(2H-tetrazol-5-yl)heptyl]oxy]phenyl]-;1-(5-Ethyl-2-hydroxy-4-((6-methyl-6-(2H-tetrazol-5-yl)heptyl)oxy)phenyl)ethan-1-one;parcnchyma,LTB4,Leukotriene Receptor,inhibit,BLT2,LY255283,lung,Inhibitor,LY-255283 | | CAS: | 117690-79-6 | | MF: | C19H28N4O3 | | MW: | 360.45 | | EINECS: | | | Product Categories: | Prostanoid receptor and related | | Mol File: | 117690-79-6.mol | ![1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone Structure](CAS/GIF/117690-79-6.gif) |
| | 1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone Chemical Properties |
| Melting point | 160-162 °C | | Boiling point | 573.4±60.0 °C(Predicted) | | density | 1.157±0.06 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMSO: >20mg/mL | | pka | 5.11±0.10(Predicted) | | form | powder | | color | off-white to light yellow | | InChI | 1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23) | | InChIKey | WCGXJPFHTHQNJL-UHFFFAOYSA-N | | SMILES | CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2 |
| WGK Germany | 2 | | Storage Class | 11 - Combustible Solids |
| | 1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone Usage And Synthesis |
| Description | Antagonists of the chemotactic and inflammatory lipoxygenase product leukotriene B4 (LTB4) have been potential drug development targets for several years. The tetrazole LY255283 is a competitive antagonist of the BLT2 receptor. It displaces radiolabeled LTB4 from guinea pig lung membrane, with an IC50 of about 100 nM. LY255283 exhibits IC50 values of ~950 nM and >10 μM at human recombinant BLT2 and BLT1 receptors, respectively. LY255283 inhibits eosinophil chemotaxis by 80% at a concentration of 10 μM, and inhibits the binding of radiolabeled LTB4 to eosinophil membranes with an IC50 of 260 nM. | | Uses | LY-255283 is a selective, competitive BLT2 receptor antagonist used in the treatment of chronic myeloid leukemia. | | Definition | ChEBI: 1-[5-ethyl-2-hydroxy-4-[6-methyl-6-(2H-tetrazol-5-yl)heptoxy]phenyl]ethanone is an aromatic ketone. | | Biological Activity | Selective, competitive antagonist of BLT 2 receptors (IC 50 values are ~ 1 and > 10 μ M at human recombinant BLT 2 and BLT 1 receptors respectively). Inhibits LTB 4 -induced contraction of lung parenchyma (pA 2 = 7.2), and reduces LTB 4 -mediated airway obstruction in guinea pigs following i.v. and oral administration. | | storage | Store at +4°C | | References | [1] STEVEN A. SILBAUGH . Pulmonary actions of LY255283, a leukotriene B4 receptor antagonist[J]. European journal of pharmacology, 1992, 223 1: Pages 57-64. DOI: 10.1016/0014-2999(92)90818-o
[2] IVAN M. RICHARDS. Contribution of Leukotriene B4 to Airway Inflammation and the Effect of Antagonists[J]. Annals of the New York Academy of Sciences, 1991, 629 1: 274-287. DOI: 10.1111/j.1749-6632.1991.tb37983.x |
| | 1-[5-Ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]ethanone Preparation Products And Raw materials |
|